Immunovaccine Announces Year-End 2017 Financial Results

Pharmaceutical Investing

Immunovaccine (TSX:IMV) a clinical stage immuno-oncology corporation, today released its financial and operational results for the fiscal year ended December 31, 2017. As quoted in the press release: “2017 was a truly pivotal year for Immunovaccine. We released our first clinical efficacy results, with the topline data for our lead product candidate, DPX-Survivac, in recurrent …

Immunovaccine (TSX:IMV) a clinical stage immuno-oncology corporation, today released its financial and operational results for the fiscal year ended December 31, 2017.

As quoted in the press release:

“2017 was a truly pivotal year for Immunovaccine. We released our first clinical efficacy results, with the topline data for our lead product candidate, DPX-Survivac, in recurrent ovarian cancer. This announcement reflects our most significant clinical milestone so far for two major reasons: it supports the potential of the novel anti-cancer activity of DPX-Survivac; and reduces the risk-profile of our future clinical developments, thus providing, we believe, a solid foundation for our ambitious development plan,” said Frederic Ors, Immunovaccine’s Chief Executive Officer.

Click here to read the full press release.

cancer dpx-survivac immuno-oncology immunovaccine oncology ovarian cancer product candidate Pharmaceutical Investing